<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885988</url>
  </required_header>
  <id_info>
    <org_study_id>BYS-IT-74</org_study_id>
    <nct_id>NCT01885988</nct_id>
  </id_info>
  <brief_title>Nebivolol Effects on Endothelial Function and Erectile Function</brief_title>
  <acronym>NEB-ED</acronym>
  <official_title>Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin M. Miner, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Miriam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will take part at The Men's Health Center It will involve men who have a diagnosis&#xD;
      of erectile dysfunction and also have high blood pressure.&#xD;
&#xD;
      High blood pressure can affect the lining of the arteries and cause stiffness in the&#xD;
      arteries. The arteries and veins throughout the body have a lining called the endothelium&#xD;
      which gives them the ability to stretch. If the lining of the penile arteries becomes&#xD;
      impaired, it can decrease the stretching of the artery and decrease blood flow. Decreased&#xD;
      blood flow in the penile arteries can cause problems obtaining an erection.&#xD;
&#xD;
      The study medication Nebivolol controls blood pressure by relaxing smooth muscle around the&#xD;
      lining of the arteries, thereby improving stretch and blood flow.&#xD;
&#xD;
      The primary objective is to determine if treatment with nebivolol improves endothelial&#xD;
      function and erectile function in men with pre-hypertension and stage 1 hypertension&#xD;
&#xD;
      70 men will be enrolled into the study. Half of the subjects will receive active medication&#xD;
      and half will receive a placebo. All men will receive educational informational handouts&#xD;
      about blood pressure and behavior modifications to improve blood pressure. The study will&#xD;
      last for 3 months for each subject. The expected recruitment time is one year, with a 2 year&#xD;
      study completion goal. Subjects will have approximately 5 study visits.&#xD;
&#xD;
      Subjects will have initial/final blood work, a Rigiscan test (a take home penile erection&#xD;
      test), two EndoPat tests to assess endothelium function, 3 SphygmoCor tests to assess central&#xD;
      blood pressure, 2 sexual health questionnaires at 2 visits. Vital signs will be monitored at&#xD;
      each visit to assess safety and effectiveness of the study medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double-blind placebo-controlled study of 70 non-smoking pre-hypertensive men (BP&#xD;
      120-139 / 80-89) or with newly diagnosed stage 1 hypertension (BP &gt; 140 but &lt; 159/ 90-99)&#xD;
      with erectile dysfunction receiving nebivolol (5-20mg) or placebo, along with lifestyle&#xD;
      modifications, daily for 3 months to titrate BP to 120/80 or less.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective is to determine if treatment with nebivolol improves endothelial function and erectile function in men with pre-hypertension and stage 1 hypertension. This will be assessed by change in IIEF-5 at baseline, 2 and 3 months</measure>
    <time_frame>baseline, 2 and 3 months</time_frame>
    <description>The evaluation of the effect of the study medication will be assessed with IIEF questionnaire. This will be assessed by change in IIEF-5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Endopat score</measure>
    <time_frame>Measurement at baseline, and 3 months</time_frame>
    <description>EndoPat test measures Endothelial function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SphygmoCor results</measure>
    <time_frame>SphygmoCor Measured at Baseline, 2 and 3 months</time_frame>
    <description>Sphygmocor will measure change in pulse wave velocity and central blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SQOLM score</measure>
    <time_frame>questionnaire administered at SphygmoCor Measured at Baseline, 2 and 3 months</time_frame>
    <description>SQOLM is the Sexual Quality of Life Male questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Males 25-65&#xD;
&#xD;
          -  Male Patients with ED (IIEF-5 ) Score &gt; 13 and &lt; 21&#xD;
&#xD;
             o If a subject is using PDE5's( phosphodiesterase type 5 inhibitors), there must be a&#xD;
             two week washout of PDE5 use, then in two weeks without PDE5 use; 4 attempts at sexual&#xD;
             activity and an IIEF score &lt; 21 on at least 2 of the four efforts&#xD;
&#xD;
          -  Treatment na√Øve patients with Pre-hypertension (BP 120-139/80-89) or&#xD;
&#xD;
          -  Stage 1 hypertension (BP &gt; 140 but &lt; 159/ 90-99)&#xD;
&#xD;
          -  Patients in a stable, monogamous relationship&#xD;
&#xD;
          -  Patients are able to comprehend and satisfactorily comply with protocol requirements&#xD;
&#xD;
          -  Eugonadal Men : Total Testosterone 300 ng/dL-1000 ng/dL or greater, as well as men who&#xD;
             are eugonadal with treatment.&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men with concomitant Type 1 or Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Normal RigiScan at Baseline&#xD;
&#xD;
          -  Concomitant use of ACE/ ARB (angiotensin receptor blocker)/ Beta-blocking agents/CCB&#xD;
             (calcium channel blocker) / alpha-blocker&#xD;
&#xD;
          -  Concomitant use of PDE5'S&#xD;
&#xD;
          -  Currently Smoking&#xD;
&#xD;
          -  Meeting any exclusion criteria for beta blocker use as stated in the nebivolol package&#xD;
             insert&#xD;
&#xD;
          -  Patients who have a medical condition that, in the Investigator's opinion, would&#xD;
             expose them to an increased risk of a significant adverse event or interfere with&#xD;
             assessments of safety and efficacy during the course of the trial.&#xD;
&#xD;
          -  Patients with any current malignancy, or any clinically significant hematological,&#xD;
             endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease.&#xD;
             If there is a history of such disease but the condition has been stable for at least&#xD;
             the past year and is judged by the investigator not to interfere with the patient's&#xD;
             participation in the study, the patient may be included.&#xD;
&#xD;
          -  Patients who are unable to speak, read, and understand English or are judged by the&#xD;
             investigator to be unable or unlikely to follow the study protocol and complete all&#xD;
             scheduled visits.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin M Miner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Miriam Hospital, a Lifespan partner</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie A Given, BSN, RN</last_name>
    <phone>401-793-4835</phone>
    <email>lgiven@lifespan.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medicine</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Wu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tony Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miriam Cardiology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Desimone, BSN, RN</last_name>
      <phone>401-793-7646</phone>
      <email>ldesimone@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Douglas Burtt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital / The Men's Health Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie A Given, BSN</last_name>
      <phone>401-793-4835</phone>
      <email>lgiven@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Martin M Miner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Miriam Hospital</investigator_affiliation>
    <investigator_full_name>Martin M. Miner, MD</investigator_full_name>
    <investigator_title>Co-Director Men's Health Center</investigator_title>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

